(Q30442724)

21 June 2017

1 reference

title

Second-line treatment of small-cell lung cancer (English)

1 reference

21 June 2017

Cecilia MacCallum

1

1 reference

21 June 2017

Heidi H Gillenwater

series ordinal

2

1 reference

21 June 2017

language of work or name

1 reference

1 July 2006

1 reference

21 June 2017

published in

Current Oncology Reports

1 reference

21 June 2017

volume

8

1 reference

21 June 2017

issue

4

1 reference

21 June 2017

page(s)

258-264

1 reference

A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer

21 June 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11912-006-0030-8

Expression of the proto-oncogenes c-met and c-kit and their ligands, hepatocyte growth factor/scatter factor and stem cell factor, in SCLC cell lines and xenografts

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11912-006-0030-8

A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study.

21 January 2018

1 reference

12 December 2020

Cancer statistics, 2005

1 reference

12 December 2020

Paclitaxel in combination with carboplatin as salvage treatment in refractory small-cell lung cancer (SCLC): a multicenter phase II study

1 reference

12 December 2020

Topotecan in the treatment of relapsed small cell lung cancer patients with poor performance status

1 reference

12 December 2020

Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571

1 reference

12 December 2020

Phase II study of vinorelbine (Navelbine) in previously treated small cell lung cancer patients. EORTC Lung Cancer Cooperative Group

1 reference

12 December 2020

Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer

1 reference

12 December 2020

Combination of irinotecan and etoposide for treatment of refractory or relapsed small-cell lung cancer

1 reference

12 December 2020

Second-line chemotherapy with weekly paclitaxel and gemcitabine in patients with small-cell lung cancer pretreated with platinum and etoposide: a single institution phase II trial

1 reference

12 December 2020

Second-line chemotherapy in small cell lung cancer in a modified administration of topotecan combined with paclitaxel: a phase II study

1 reference

12 December 2020

Phase II trial of gemcitabine in refractory or relapsed small-cell lung cancer: Eastern Cooperative Oncology Group Trial 1597.

1 reference

12 December 2020

Emerging role of weekly topotecan in recurrent small cell lung cancer

1 reference

12 December 2020

Hematologic safety and tolerability of topotecan in recurrent ovarian cancer and small cell lung cancer: an integrated analysis

1 reference

12 December 2020

Treatment of relapsed small-cell lung cancer--a focus on the evolving role of topotecan

1 reference

12 December 2020

Phase ii comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer

1 reference

12 December 2020

Autocrine growth of small cell lung cancer mediated by coexpression of c-kit and stem cell factor.

1 reference

12 December 2020

Phase II study of imatinib in patients with small cell lung cancer.

1 reference

12 December 2020

Coexpression of the stem cell factor and the c-kit genes in small-cell lung cancer

1 reference

12 December 2020

European organization for research and treatment of cancer (EORTC) 08957 phase II study of topotecan in combination with cisplatin as second-line treatment of refractory and sensitive small cell lung cancer.

1 reference

12 December 2020

Preferential expression of c-kit protooncogene transcripts in small cell lung cancer

1 reference

12 December 2020

Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and

1 reference

12 December 2020

Chemotherapy of small cell lung cancer: state of the art.

1 reference

12 December 2020

Options for first- and second-line therapy in small cell lung cancer — a workshop discussion

1 reference

12 December 2020

10.1007/S11912-006-0030-8

Identifiers

DOI

1 reference

Dimensions Publication ID

21 June 2017

1013213071

0 references

1 reference